A retrospective analysis of changes in lymphocyte levels in patients with multiple sclerosis during and after Tecfidera® treatment

BACKGROUND: There are currently no best practice recommendations for lymphocyte subset monitoring for patients with multiple sclerosis (pwMS) on disease-modifying therapies including Tecfidera® (dimethyl fumarate, DMF). However, there have been several cases of pwMS on DMF without severe lymphopenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Baeva, Maria-Elizabeth, Baev, Philip Boris, Nelson, Jill, Kazimirchik, Anna, Vorobeychik, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283074/
https://www.ncbi.nlm.nih.gov/pubmed/34345437
http://dx.doi.org/10.1177/20552173211029674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283074/
https://www.ncbi.nlm.nih.gov/pubmed/34345437
http://dx.doi.org/10.1177/20552173211029674

Ejemplares similares